{"name": "Epizyme",
 "permalink": "epizyme",
 "crunchbase_url": "http://www.crunchbase.com/company/epizyme",
 "homepage_url": "http://www.epizyme.com",
 "blog_url": "http://www.epizyme.com/news-events/press-releases.asp",
 "blog_feed_url": "",
 "twitter_username": "RobertJGould",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2007,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "cancer, blood, biotech",
 "alias_list": "",
 "email_address": "",
 "phone_number": "",
 "description": "Blood Cancer and Tumor Treatments",
 "created_at": "Wed Oct 07 22:46:54 UTC 2009",
 "updated_at": "Wed Mar 27 08:40:23 UTC 2013",
 "overview": "\u003Cp\u003EEpizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors.\u003C/p\u003E\n\n\u003Cp\u003EFounded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       74],
      "assets/images/resized/0006/1969/61969v1-max-150x150.jpg"],
     [[250,
       124],
      "assets/images/resized/0006/1969/61969v1-max-250x250.jpg"],
     [[450,
       224],
      "assets/images/resized/0006/1969/61969v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$51.5M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.fiercebiotech.com/story/epizyme-pulls-32m-vc-capital-new-investors/2009-10-07?utm_medium=rss\u0026utm_source=rss\u0026cmp-id=OTC-RSS-FB0#ixzz0TIDqj9B1",
    "source_description": "Epizyme pulls in $32M in VC capital, new investors",
    "raised_amount": 32000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 10,
    "funded_day": 7,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Bay City Capital",
         "permalink": "bay-city-capital",
         "image":
          {"available_sizes":
            [[[150,
               24],
              "assets/images/resized/0004/8963/48963v1-max-150x150.png"],
             [[219,
               36],
              "assets/images/resized/0004/8963/48963v1-max-250x250.png"],
             [[219,
               36],
              "assets/images/resized/0004/8963/48963v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Amgen Ventures",
         "permalink": "amgen-ventures",
         "image":
          {"available_sizes":
            [[[150,
               28],
              "assets/images/resized/0023/2414/232414v2-max-150x150.jpg"],
             [[250,
               47],
              "assets/images/resized/0023/2414/232414v2-max-250x250.jpg"],
             [[450,
               84],
              "assets/images/resized/0023/2414/232414v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Astellas Venture Management",
         "permalink": "astellas-venture-management",
         "image":
          {"available_sizes":
            [[[150,
               60],
              "assets/images/resized/0004/6637/46637v3-max-150x150.png"],
             [[160,
               64],
              "assets/images/resized/0004/6637/46637v3-max-250x250.png"],
             [[160,
               64],
              "assets/images/resized/0004/6637/46637v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "MPM Capital",
         "permalink": "mpm-capital",
         "image":
          {"available_sizes":
            [[[150,
               142],
              "assets/images/resized/0004/5561/45561v1-max-150x150.png"],
             [[180,
               171],
              "assets/images/resized/0004/5561/45561v1-max-250x250.png"],
             [[180,
               171],
              "assets/images/resized/0004/5561/45561v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Kleiner Perkins Caufield \u0026 Byers",
         "permalink": "kleiner-perkins-caufield-byers",
         "image":
          {"available_sizes":
            [[[150,
               150],
              "assets/images/resized/0001/0998/10998v8-max-150x150.jpg"],
             [[250,
               250],
              "assets/images/resized/0001/0998/10998v8-max-250x250.jpg"],
             [[450,
               450],
              "assets/images/resized/0001/0998/10998v8-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://www.fiercebiotech.com/story/epizyme-amps-series-b-40m/2009-12-08?utm_medium=rss\u0026utm_source=rss\u0026cmp-id=OTC-RSS-FB0",
    "source_description": "Epizyme amps up Series B to $40M",
    "raised_amount": 8000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 12,
    "funded_day": 8,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "New Enterprise Associates",
         "permalink": "new-enterprise-associates",
         "image":
          {"available_sizes":
            [[[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-150x150.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-250x250.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2011/06/20/daily36-Epizyme-to-land-75M-from-Leukemia--Lymphoma-Society.html",
    "source_description": "Epizyme to land $7.5M from Leukemia \u0026 Lymphoma Society",
    "raised_amount": 7500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 6,
    "funded_day": 23,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Leukemia \u0026 Lymphoma Society",
         "permalink": "leukemia-lymphoma-society",
         "image":
          {"available_sizes":
            [[[150,
               30],
              "assets/images/resized/0027/0240/270240v1-max-150x150.png"],
             [[250,
               51],
              "assets/images/resized/0027/0240/270240v1-max-250x250.png"],
             [[435,
               89],
              "assets/images/resized/0027/0240/270240v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://www.epizyme.com/news-events/press-release_2011-11-14.asp",
    "source_description": " Epizyme Achieves $4 Million in Pre-Clinical Milestone Payments in GlaxoSmithKline Alliance to Discover and Develop Novel HMT Therapeutics ",
    "raised_amount": 4000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 10,
    "funded_day": 14,
    "investments":
     [{"company":
        {"name": "GlaxoSmithKline",
         "permalink": "glaxosmithkline",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0005/1020/51020v1-max-150x150.png"],
             [[158,
               54],
              "assets/images/resized/0005/1020/51020v1-max-250x250.png"],
             [[158,
               54],
              "assets/images/resized/0005/1020/51020v1-max-450x450.png"]],
           "attribution": null}},
       "financial_org": null,
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "",
    "address2": "",
    "zip_code": "",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "received $1 million research award from the Multiple Myeloma Research Foundation",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 7,
    "source_url": "http://www.masshightech.com/stories/2011/01/03/daily63-Three-Mass-biotechs-get-1M-from-myeloma-foundation.html",
    "source_text": null,
    "source_description": "Three Mass. biotechs get $1M from myeloma foundation",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Epizyme",
      "permalink": "epizyme"}},
   {"description": "has entered into a cancer therapeutics development and commercialization alliance with GlaxoSmithKline worth potentially more than $630 million in milestone payments",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 10,
    "source_url": "http://www.masshightech.com/stories/2011/01/10/daily8-Epizyme-enters-lucrative-GSK-alliance.html",
    "source_text": null,
    "source_description": "Epizyme enters lucrative GSK alliance",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Epizyme",
      "permalink": "epizyme"}},
   {"description": "Epizyme snags $206M epigenetics deal with Eisai",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 10,
    "source_url": "http://www.fiercebiotech.com/story/epizyme-snags-206m-epigenetics-deal-eisai/2011-03-10?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Epizyme snags $206M epigenetics deal with Eisai",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Epizyme",
      "permalink": "epizyme"}},
   {"description": "Epizyme joins Celgene in $90M-plus partnership",
    "stoned_year": 2012,
    "stoned_month": 4,
    "stoned_day": 26,
    "source_url": "http://www.masshightech.com/stories/2012/04/23/daily48-Epizyme-joins-Celgene-in-90M-plus-partnership.html",
    "source_text": "",
    "source_description": "Epizyme joins Celgene in $90M-plus partnership",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Epizyme",
      "permalink": "epizyme"}},
   {"description": "Epizyme receives $4M, publishes research",
    "stoned_year": 2012,
    "stoned_month": 10,
    "stoned_day": 3,
    "source_url": "http://www.masshightech.com/stories/2012/10/01/daily33-Epizyme-receives-4M-publishes-research.html",
    "source_text": "",
    "source_description": "Epizyme receives $4M, publishes research",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Epizyme",
      "permalink": "epizyme"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        82],
       "assets/images/resized/0006/8956/68956v1-max-150x150.jpg"],
      [[250,
        137],
       "assets/images/resized/0006/8956/68956v1-max-250x250.jpg"],
      [[450,
        246],
       "assets/images/resized/0006/8956/68956v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}